IMNM
HealthcareImmunome, Inc.
$19.71
$-1.11 (-5.33%)
Jan 5, 2026
Price History (1Y)
Analysis
Immunome, Inc. is a healthcare company operating in the biotechnology industry. The company has a significant market presence with a market capitalization of $2.17B and generates revenue of $9.68M (TTM). It employs approximately 168 people. The company's financial health is marked by negative profitability metrics. Immunome, Inc. reports an Operating Margin of -2137.1% (TTM) and a Profit Margin of 0.0%. Return on Equity (ROE) stands at -93.0%, while Return on Assets (ROA) is -46.5%. The company's balance sheet shows $272.64M in cash and $4.01M in debt, resulting in a Debt to Equity ratio of 1.52. The valuation context for Immunome, Inc. reveals a negative Forward P/E Ratio of -7.69 and an EV/EBITDA of -8.02. The Price to Book ratio is 6.85, while the Price to Sales ratio is 224.68. The company's stock price has fluctuated between $5.15 (52-Week Low) and $25.30 (52-Week High), with a Beta of 2.23 indicating higher volatility compared to the market average.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Immunome, Inc.
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Visit website →Key Statistics
- Market Cap
- $2.17B
- P/E Ratio
- N/A
- 52-Week High
- $25.30
- 52-Week Low
- $5.15
- Avg Volume
- 1.87M
- Beta
- 2.23
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 168